Justin D. Boyd

Justin D. Boyd

Auto-generated profile, based on publicly available information

Justin D. Boyd

Pfizer Worldwide Research, Development and Medical, Cambridge, MA, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
KRKatie J. Ryan
Katie J. Ryan
CWCharles C. White
Charles C. White
KPKruti Patel
Kruti Patel
JXJishu Xu
Jishu Xu
MOMarta Olah
Marta Olah
EBElizabeth M. Bradshaw
Elizabeth M. Bradshaw
Microglia are emerging as a key cell type in neurodegenerative diseases, yet human microglia are challenging to study in vitro. We developed an in vitro cell model system composed of human monocyte-derived microglia-like (MDMi) cells that recapitulated key aspects of microglia phenotype and function. We then used this model system to perform an expression quantitative trait locus (eQTL) study examining 94 genes from loci associated with Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis. We found six loci (CD33, PILRB, NUP160, LRRK2, RGS1, and METTL21B) in which the risk haplotype drives the association with both disease susceptibility and altered expression of a nearby gene (cis-eQTL). In the PILRB and LRRK2 loci, the cis-eQTL was found in the MDMi cells but not in human peripheral blood monocytes, suggesting that differentiation of monocytes into microglia-like cells led to the acquisition of a cellular state that could reveal the functional consequences of certain genetic variants. We further validated the effect of risk haplotypes at the protein level for PILRB and CD33, and we confirmed that the CD33 risk haplotype altered phagocytosis by the MDMi cells. We propose that increased LRRK2 gene expression by MDMi cells could be a functional outcome of rs76904798, a single-nucleotide polymorphism in the LRKK2 locus that is associated with Parkinson’s disease.

1 March 2018 in Neurobiology of Disease
Verified
Journal Article
Closed access
JSJason Schapansky
Jason Schapansky
SKSaurabh Khasnavis
Saurabh Khasnavis
MDMark P. DeAndrade
Mark P. DeAndrade
JNJonathan D. Nardozzi
Jonathan D. Nardozzi
SFSamuel R. Falkson
Samuel R. Falkson
MLMatthew J. LaVoie
Matthew J. LaVoie

1 September 2015 in Cell Reports
Verified
Journal Article
Open access
PSPriya Srikanth
Priya Srikanth
KHKaram Han
Karam Han
DCDana G. Callahan
Dana G. Callahan
EMEugenia Makovkina
Eugenia Makovkina
CMChristina R. Muratore
Christina R. Muratore
TYTracy L. Young-Pearse
Tracy L. Young-Pearse
Genetic and clinical association studies have identified disrupted in schizophrenia 1 (DISC1) as a candidate risk gene for major mental illness. DISC1 is interrupted by a balanced chr(1;11) translocation in a Scottish family in which the translocation predisposes to psychiatric disorders. We investigate the consequences of DISC1 interruption in human neural cells using TALENs or CRISPR-Cas9 to target the DISC1 locus. We show that disruption of DISC1 near the site of the translocation results in decreased DISC1 protein levels because of nonsense-mediated decay of long splice variants. This results in an increased level of canonical Wnt signaling in neural progenitor cells and altered expression of fate markers such as Foxg1 and Tbr2. These gene expression changes are rescued by antagonizing Wnt signaling in a critical developmental window, supporting the hypothesis that DISC1-dependent suppression of basal Wnt signaling influences the distribution of cell types generated during cortical development.

24 March 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
SCSrinivas Niranj Chandrasekaran
Srinivas Niranj Chandrasekaran
JAJeanelle Ackerman
Jeanelle Ackerman
EAEric Alix
Eric Alix
DAD. Michael Ando
D. Michael Ando
JAJohn Arevalo
John Arevalo
ACAnne E. Carpenter
Anne E. Carpenter
Image-based profiling decodes complex cellular states for high-impact biological and therapeutic applications, yet a large, public reference dataset of chemical perturbations has been lacking. We present Cell Painting images and 1.53 billion single-cell profiles for 115,796 compounds in human osteosarcoma cells, generated by the Joint Undertaking for Morphological Profiling (JUMP)-Cell Painting Consortium of 18 industry and non-profit partners. Despite technical variability across 12 data-generating laboratories, more than 15% of compounds show statistically significant phenotypic activity, reproducibility drops only 34% versus single-laboratory data, and compounds sharing biological targets often show similar image-based profiles. JUMP establishes a validated public reference resource that brings image-based profiling on par with genomics and transcriptomics. The dataset, shared alongside previously released genetic perturbation data in the Cell Painting Gallery, is a powerful predictive engine for the impact, mechanism, targets and activities of compounds, fundamentally accelerating chemical and cell biology and early-stage drug development.

1 October 2011 in Journal of Biological Chemistry
Verified
Journal Article
Open access
KWKim Wilkinson
Kim Wilkinson
JBJustin D. Boyd
Justin D. Boyd
MGMarcie Glicksman
Marcie Glicksman
KMKathryn J. Moore
Kathryn J. Moore
JKJoseph El Khoury
Joseph El Khoury
A pathological hallmark of Alzheimer disease (AD) is deposition of amyloid β (Aβ) in the brain. Aβ binds to microglia via a receptor complex that includes CD36 leading to production of proinflammatory cytokines and neurotoxic reactive oxygen species and subsequent neurodegeneration. Interruption of Aβ binding to CD36 is a potential therapeutic strategy for AD. To identify pharmacologic inhibitors of Aβ binding to CD36, we developed a 384-well plate assay for binding of fluorescently labeled Aβ to Chinese hamster ovary cells stably expressing human CD36 (CHO-CD36) and screened an Food and Drug Administration-approved compound library. The assay was optimized based on the cells' tolerance to dimethyl sulfoxide, Aβ concentration, time required for Aβ binding, reproducibility, and signal-to-background ratio. Using this assay, we identified four compounds as potential inhibitors of Aβ binding to CD36. These compounds were ursolic acid, ellipticine, zoxazolamine, and homomoschatoline. Of these compounds, only ursolic acid, a naturally occurring pentacyclic triterpenoid, successfully inhibited binding of Aβ to CHO-CD36 cells in a dose-dependent manner. The ursolic acid effect reached a plateau at ~20 μm, with a maximal inhibition of 64%. Ursolic acid also blocked binding of Aβ to microglial cells and subsequent ROS production. Our data indicate that cell-based high-content screening of small molecule libraries for their ability to block binding of Aβ to its receptors is a useful tool to identify novel inhibitors of receptors involved in AD pathogenesis. Our data also suggest that ursolic acid is a potential therapeutic agent for AD via its ability to block Aβ-CD36 interactions.

6 February 2007 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
MSMichelle Smeyne
Michelle Smeyne
JBJustin Boyd
Justin Boyd
KSKennie Raviie Shepherd
Kennie Raviie Shepherd
YJYun Jiao
Yun Jiao
BPBrooks Barnes Pond
Brooks Barnes Pond
RSRichard Jay Smeyne
Richard Jay Smeyne
The cause of 95% of Parkinson's disease (PD) cases is unknown. It is hypothesized that PD arises from an interaction of free-radical-generating agents with an underlying genetic susceptibility to these compounds. Here we use the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of parkinsonism to examine the role of a dual function protein, GSTπ, in dopaminergic neuron death. GSTπ is the only GST family member expressed in substantia nigra neurons. GSTπ reduction by pharmacological blockade, RNA inhibition, and gene targeting increases sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, suggesting that differential expression of GSTπ contributes to the sensitivity to xenobiotics in the substantia nigra and may influence the pathogenesis of reactive oxygen species-induced neurological disorders including PD.